BRPI0116865B8 - composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta - Google Patents
composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso destaInfo
- Publication number
- BRPI0116865B8 BRPI0116865B8 BRPI0116865A BR0116865A BRPI0116865B8 BR PI0116865 B8 BRPI0116865 B8 BR PI0116865B8 BR PI0116865 A BRPI0116865 A BR PI0116865A BR 0116865 A BR0116865 A BR 0116865A BR PI0116865 B8 BRPI0116865 B8 BR PI0116865B8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- prevention
- treatment
- bone diseases
- preparing
- Prior art date
Links
- 208000029725 Metabolic bone disease Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 4
- 229940122361 Bisphosphonate Drugs 0.000 title abstract 3
- 150000004663 bisphosphonates Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000230 xanthan gum Substances 0.000 abstract 1
- 229920001285 xanthan gum Polymers 0.000 abstract 1
- 229940082509 xanthan gum Drugs 0.000 abstract 1
- 235000010493 xanthan gum Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3843—Polyphosphonic acids containing no further substituents than -PO3H2 groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/386—Polyphosphonic acids containing hydroxy substituents in the hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta". o presente invento se refere a uma composição para a prevenção e/ou o tratamento de doenças metabólicas dos ossos, compreendendo pelo menos um bisfosfonato; agentes de viscosidade compreendendo carboximetilcelulose e goma xantana; pelo menos um agente flavorizante; e água purificada; um processo para preparar uma composição de acordo com o presente invento; e ao uso de tal composição para prevenção, tratamento e/ou diagnose de doenças metabólicas dos ossos, especialmente para crianças.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2001/000690 WO2002058708A1 (en) | 2001-01-23 | 2001-01-23 | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0116865A BR0116865A (pt) | 2004-02-25 |
BR0116865B1 BR0116865B1 (pt) | 2014-03-11 |
BRPI0116865B8 true BRPI0116865B8 (pt) | 2021-05-25 |
Family
ID=8164260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0116865A BRPI0116865B8 (pt) | 2001-01-23 | 2001-01-23 | composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta |
Country Status (13)
Country | Link |
---|---|
US (2) | US7560490B2 (pt) |
EP (1) | EP1372669B1 (pt) |
JP (1) | JP2004519463A (pt) |
KR (1) | KR100593510B1 (pt) |
AR (1) | AR047480A1 (pt) |
AT (1) | ATE297740T1 (pt) |
BR (1) | BRPI0116865B8 (pt) |
CA (1) | CA2431515C (pt) |
DE (1) | DE60111574T2 (pt) |
DK (1) | DK1372669T3 (pt) |
ES (1) | ES2243457T3 (pt) |
MX (1) | MXPA03006565A (pt) |
WO (1) | WO2002058708A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2431515C (en) * | 2001-01-23 | 2008-01-22 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof |
JP2005514400A (ja) * | 2001-12-21 | 2005-05-19 | ザ プロクター アンド ギャンブル カンパニー | 骨疾患の治療方法 |
KR20060058151A (ko) * | 2002-05-10 | 2006-05-29 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
SI1596870T2 (sl) * | 2002-12-20 | 2011-07-29 | Hoffmann La Roche | Formulacija z visokim odmerkom ibandronata |
WO2006039721A2 (en) * | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8012949B2 (en) * | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
JP2009530414A (ja) * | 2006-03-17 | 2009-08-27 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | ビスホスホネート化合物及び方法 |
DK1894557T3 (da) * | 2006-09-04 | 2011-05-30 | Gador Sa | Flydende sammensætning til behandling og/eller forebyggelse af forskellige metaboliske knoglesygdomme, anvendelse heraf og fremgangsmåde til fremstilling heraf |
WO2009100107A2 (en) * | 2008-02-05 | 2009-08-13 | Actavis Group Ptc Ehf | Alendronate formulations, method of making and method of use thereof |
FI20115315A0 (fi) * | 2011-04-01 | 2011-04-01 | Itae Suomen Yliopisto | Menetelmä metallien keräämiseksi |
CN105410940B (zh) * | 2015-12-27 | 2018-08-24 | 山东阜丰发酵有限公司 | 一种包含黄原胶的保健食品 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2405254C2 (de) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
US4313765A (en) * | 1980-09-24 | 1982-02-02 | Merck & Co., Inc. | Synergistic blends of cellulase-free xanthan gum and cellulosics |
US4446052A (en) | 1982-05-17 | 1984-05-01 | The Procter & Gamble Company | Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate |
US4639338A (en) | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
US4788220A (en) | 1987-07-08 | 1988-11-29 | American Home Products Corporation (Del.) | Pediatric ibuprofen compositions |
FR2629716B1 (fr) * | 1988-04-07 | 1991-07-19 | Sanofi Sa | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique |
FI89364C (fi) | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
HU227530B1 (en) * | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
TW237386B (pt) | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
JP3332426B2 (ja) | 1992-10-02 | 2002-10-07 | 太田製薬株式会社 | 大腸および小腸の検査用x線造影剤 |
PT721335E (pt) * | 1993-10-01 | 2005-11-30 | Roche Palo Alto Llc | Suspensoes orais em altas doses de micofenolato de mofetil |
US5674522A (en) * | 1993-10-07 | 1997-10-07 | Mcneil-Ppc, Inc. | Beverage concentrate for drug delivery |
EP0813414A4 (en) * | 1993-10-19 | 1999-07-21 | Merck & Co Inc | COMBINATION OF BISPHOSPHONATES AND THE GROWTH HORMONE SECRETION PROMOTING SUBSTANCES |
US5462932A (en) | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
ZA956029B (en) * | 1994-07-22 | 1997-01-20 | Lilly Co Eli | Combination treatment for inhibiting bone loss |
DE69534923T2 (de) * | 1994-12-28 | 2006-11-23 | Gador S.A. | Anabolische zubereitung für knochenmasse enthaltend olpadronat |
JPH08333245A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
TW442287B (en) * | 1995-06-13 | 2001-06-23 | American Home Produits Corp | Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac) |
BR9712197A (pt) * | 1996-10-04 | 1999-08-31 | Merck & Co Inc | Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso. |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
GB9815532D0 (en) * | 1998-07-17 | 1998-09-16 | Lek Pharmaceutical & Cvhemical | Pharmaceutical suspension formulation |
CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
CN1372468A (zh) * | 1999-06-02 | 2002-10-02 | 宝洁公司 | 羟乙磷酸二钠口服制剂 |
US20020002169A1 (en) * | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
WO2002049451A2 (en) * | 2000-12-18 | 2002-06-27 | Societe Des Produits Nestle S.A. | Stabilizer based on microcrystalline cellulose for drink and dressing formulations |
CA2431515C (en) * | 2001-01-23 | 2008-01-22 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof |
-
2001
- 2001-01-23 CA CA002431515A patent/CA2431515C/en not_active Expired - Lifetime
- 2001-01-23 MX MXPA03006565A patent/MXPA03006565A/es active IP Right Grant
- 2001-01-23 ES ES01911512T patent/ES2243457T3/es not_active Expired - Lifetime
- 2001-01-23 BR BRPI0116865A patent/BRPI0116865B8/pt not_active IP Right Cessation
- 2001-01-23 US US10/466,897 patent/US7560490B2/en not_active Expired - Lifetime
- 2001-01-23 WO PCT/EP2001/000690 patent/WO2002058708A1/en active IP Right Grant
- 2001-01-23 AT AT01911512T patent/ATE297740T1/de not_active IP Right Cessation
- 2001-01-23 EP EP01911512A patent/EP1372669B1/en not_active Expired - Lifetime
- 2001-01-23 KR KR1020037009642A patent/KR100593510B1/ko active IP Right Grant
- 2001-01-23 DE DE60111574T patent/DE60111574T2/de not_active Expired - Lifetime
- 2001-01-23 DK DK01911512T patent/DK1372669T3/da active
- 2001-01-23 JP JP2002559042A patent/JP2004519463A/ja active Pending
-
2002
- 2002-01-17 AR ARP020100154A patent/AR047480A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 US US12/480,086 patent/US8853187B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK1372669T3 (da) | 2005-10-17 |
BR0116865B1 (pt) | 2014-03-11 |
ATE297740T1 (de) | 2005-07-15 |
EP1372669B1 (en) | 2005-06-15 |
DE60111574D1 (de) | 2005-07-21 |
ES2243457T3 (es) | 2005-12-01 |
CA2431515A1 (en) | 2002-08-01 |
AR047480A1 (es) | 2006-01-25 |
WO2002058708A1 (en) | 2002-08-01 |
BR0116865A (pt) | 2004-02-25 |
MXPA03006565A (es) | 2005-07-29 |
JP2004519463A (ja) | 2004-07-02 |
EP1372669A1 (en) | 2004-01-02 |
KR100593510B1 (ko) | 2006-06-28 |
US20040087550A1 (en) | 2004-05-06 |
US20090247491A1 (en) | 2009-10-01 |
DE60111574T2 (de) | 2006-05-11 |
CA2431515C (en) | 2008-01-22 |
KR20030086988A (ko) | 2003-11-12 |
US8853187B2 (en) | 2014-10-07 |
US7560490B2 (en) | 2009-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
ATE374029T1 (de) | Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo | |
EP1024145A3 (en) | Novel azalides and methods of making same | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
ATE297204T1 (de) | Heilmittel für neurodegenerative krankheiten | |
BR0107755A (pt) | Composição parenteral, processo para preparação e utilização dessa composição, processo para o tratamento e prevenção de enfermidades que, envolvem ressorção óssea e dispositivo para liberação local e sistêmica sustentada | |
CA2427227A1 (en) | Lactam compound | |
YU92501A (sh) | Levodop/karbidop/entakapon farmaceutski preparat | |
BR9914638A (pt) | Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo | |
BR0016058A (pt) | Compostos de fosfonato | |
BR0214705A (pt) | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
BRPI9710372B8 (pt) | composto, e, composição farmacêutica. | |
BG104644A (en) | Novel macrolides | |
ES2162319T3 (es) | Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer. | |
BRPI0116865B8 (pt) | composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta | |
BRPI0408655A (pt) | formulações compreendendo um agente ativo e cacau em pó e a sua utilização | |
DE602004031163D1 (de) | Phenylcarboxamidverbindungen zur Schmerzbehandlung | |
BR0209327A (pt) | Composição para tratamento de constipação induzida por drogas | |
BR0208727A (pt) | Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia | |
PT1051159E (pt) | Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose | |
BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
DE60334711D1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
BRPI0409151A (pt) | uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos | |
BR9914644A (pt) | Composições tamponadas para diálise |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 23/01/2021 |